← Patent-cliff monitor small molecule RIVFLOZA NEDOSIRAN SODIUM
Loss of exclusivity October 2038 latest FDA-listed patent expiry
Company NOVO NORDISK INC
Drug detail Brand name RIVFLOZA Active ingredient NEDOSIRAN SODIUM Strength EQ 160MG BASE/ML (EQ 160MG BASE/ML) Dosage form SOLUTION Route INJECTION Modality Small molecule FDA approval September 2023 Marketing status RX
Listed patents Patent Expires Type 11661604 October 2038 substance, product 11286488 October 2038 substance, product 11053502 October 2035 substance, product 11359203 October 2035 substance, product 10738311 October 2035 substance, product 10351854 October 2035 substance, product
Regulatory exclusivity Code Expires ODE-531 March 2032 ODE-443 September 2030 NCE September 2028 NPP March 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.